Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
Multiple Myeloma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.9
2 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 37 (final count)
- Started
- Jan 24, 2019
- Main results expected
- Dec 6, 2023
- Fully finished
- Dec 6, 2023
- Results posted
- Mar 21, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants Categorized According to Performance Status (PS) Based on Eastern Cooperative Oncology Group (ECOG) PS
Measured over: Month 25
Percentage of Participants Receiving Ixazomib With Treatment-emergent Adverse Events (TEAEs)
Measured over: Up to 58.4 months
Percentage of Participants Receiving Ixazomib With Treatment-emergent Serious Adverse Events (SAEs)
Measured over: Up to 58.4 months
Number of Participants Receiving Ixazomib With Clinically Significant Changes in Safety Laboratory Values
Measured over: Up to 58.4 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.9, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03748953 · record last updated 2025-03-21 · checked 2026-11-09 15:47 UTC